Astellas Pharma (OTCMKTS:ALPMY) Lowered to “Hold” Rating by Zacks Research

Astellas Pharma (OTCMKTS:ALPMY) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

ALPMY has been the topic of several other reports. Smbc Nikko Sec. raised Astellas Pharma to a “hold” rating in a report on Monday, February 16th. Jefferies Financial Group raised shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold”.

Astellas Pharma Stock Performance

Shares of OTCMKTS:ALPMY opened at $13.93 on Monday. The company has a quick ratio of 0.84, a current ratio of 1.09 and a debt-to-equity ratio of 0.23. Astellas Pharma has a 12-month low of $9.11 and a 12-month high of $17.35. The company’s 50 day moving average price is $15.35 and its two-hundred day moving average price is $14.48. The firm has a market cap of $25.21 billion, a PE ratio of 12.97 and a beta of 0.08.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings results on Monday, April 27th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.14. Astellas Pharma had a return on equity of 24.19% and a net margin of 13.66%.The business had revenue of $3.38 billion during the quarter, compared to analysts’ expectations of $3.28 billion. Equities research analysts predict that Astellas Pharma will post 1.29 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).